Trial · NCT01802333
Participant flow21
How many started, completed or left each group, period by period.
1 to 20 of 21
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Arm I (Standard Dose Cytarabine, Daunorubicin Hydrochloride) | 263 | |
| Overall Study | STARTED | Arm II (High-dose Cytarabine, Idarubicin) | 267 | |
| Overall Study | STARTED | Arm III (Vorinostat, High-dose Cytarabine, Idarubicin) | 224 | |
| Overall Study | High Risk Patients | Arm I (Standard Dose Cytarabine, Daunorubicin Hydrochloride) | 60 | |
| Overall Study | High Risk Patients | Arm II (High-dose Cytarabine, Idarubicin) | 61 | |
| Overall Study | High Risk Patients | Arm III (Vorinostat, High-dose Cytarabine, Idarubicin) | 38 | |
| Overall Study | High Risk Patients Achieved CR/CRi | Arm I (Standard Dose Cytarabine, Daunorubicin Hydrochloride) | 38 | |
| Overall Study | High Risk Patients Achieved CR/CRi | Arm II (High-dose Cytarabine, Idarubicin) | 40 | |
| Overall Study | High Risk Patients Achieved CR/CRi | Arm III (Vorinostat, High-dose Cytarabine, Idarubicin) | 29 | |
| Overall Study | Known NPM1 Status at Baseline | Arm I (Standard Dose Cytarabine, Daunorubicin Hydrochloride) | 169 | |
| Overall Study | Known NPM1 Status at Baseline | Arm II (High-dose Cytarabine, Idarubicin) | 156 | |
| Overall Study | Known NPM1 Status at Baseline | Arm III (Vorinostat, High-dose Cytarabine, Idarubicin) | 142 | |
| Overall Study | Known Cytogenetic Risk at Baseline | Arm I (Standard Dose Cytarabine, Daunorubicin Hydrochloride) | 252 | |
| Overall Study | Known Cytogenetic Risk at Baseline | Arm II (High-dose Cytarabine, Idarubicin) | 250 | |
| Overall Study | Known Cytogenetic Risk at Baseline | Arm III (Vorinostat, High-dose Cytarabine, Idarubicin) | 210 | |
| Overall Study | COMPLETED | Arm I (Standard Dose Cytarabine, Daunorubicin Hydrochloride) | 214 | |
| Overall Study | COMPLETED | Arm II (High-dose Cytarabine, Idarubicin) | 206 | |
| Overall Study | COMPLETED | Arm III (Vorinostat, High-dose Cytarabine, Idarubicin) | 161 | |
| Overall Study | NOT COMPLETED | Arm I (Standard Dose Cytarabine, Daunorubicin Hydrochloride) | 49 | |
| Overall Study | NOT COMPLETED | Arm II (High-dose Cytarabine, Idarubicin) | 61 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01802333/flow